A5079436601- Breast Cancer Treatment Studies
- BRCA gene mutations in cancer
- Breast Implant and Reconstruction
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Ovarian cancer diagnosis and treatment
- Nutrition, Genetics, and Disease
- Cancer Risks and Factors
- Reconstructive Surgery and Microvascular Techniques
- Advanced Breast Cancer Therapies
- Complementary and Alternative Medicine Studies
- Cancer survivorship and care
- Breast Lesions and Carcinomas
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- DNA Repair Mechanisms
- Monoclonal and Polyclonal Antibodies Research
- Chemokine receptors and signaling
- Epigenetics and DNA Methylation
- Peptidase Inhibition and Analysis
- Economic and Financial Impacts of Cancer
- Genetic factors in colorectal cancer
- Health and Medical Studies
- Endometrial and Cervical Cancer Treatments
- Global Cancer Incidence and Screening
Technical University of Munich
2016-2025
Klinikum rechts der Isar
2015-2024
Klinik für Frauenheilkunde
2010-2024
München Klinik
2010-2023
Ludwig-Maximilians-Universität München
2002-2022
Science Club
2022
Starnberg Hospital
2022
Universitäts Frauenklinik
1996-2020
Olgahospital
2004-2019
Charité - Universitätsmedizin Berlin
2009-2019
Purpose To estimate the risk for contralateral breast cancer in members of BRCA1- and BRCA2-positive families to determine predictive factors. Patients Methods A retrospective, multicenter, cohort study was performed from 1996 until 2008 comprised 2,020 women with unilateral (index patients, n = 978; relatives, 1.42) 978 who had a BRCA1 or BRCA2 mutation. Cox regression analysis applied assess association age at first time cancer, stratified by affected BRCA gene. Results The cumulative 25...
Tumour-infiltrating lymphocytes (TILs) are associated with improved survival in several epithelial cancers. The two chemokines CXCL9 and CXCL10 facilitate chemotactic recruitment of TILs, their intratumoral accumulation is a conceivable way to improve TIL-dependent immune intervention cancer. However, the prognostic impact high-grade serous ovarian cancer (HGSC) largely unknown. One hundred eighty four cases HGSC were immunohistochemically analyzed for CXCL9, CXCL10. TILs assessed using CD3,...
<h3>Purpose</h3> To characterise the prevalence of pathogenic germline mutations in <i>BRCA1</i> and <i>BRCA2</i> families with breast cancer (BC) ovarian (OC) history. <h3>Patients methods</h3> Data from 21 401 were gathered between 1996 2014 a clinical setting German Consortium for Hereditary Breast Ovarian Cancer, comprising full pedigrees status all individual members at time first counselling, <i>BRCA1/2</i> mutation index patient. <h3>Results</h3> The overall was 24.0% (95% CI 23.4% to...
The International Consensus Conference on the treatment of primary breast cancer takes place every two years in St. Gallen, Switzerland. panel Gallen is composed international experts from different countries. From a German perspective, it seems reasonable to interpret voting results light AGO-recommendations and S3-guidelines for everyday practice Germany. Consequently, team eight experts, whom are members panel, commented (2013). main topics at this year's conference were surgical issues...
In the last decade, health care sector has been enriched by numerous innovations such as apps and connected devices that assist users in weight reduction diabetes management. However, only a few native oncological context exist, which support patients during treatment aftercare.The objective of this study was to analyze patients' acceptance regarding app use investigate functions an are most required, primary reasons for refuse app-assisted cancer care.We designed conducted survey with 23...
Abstract Introduction While it has been reported that the risk of contralateral breast cancer in patients from BRCA1 or BRCA2 positive families is elevated, little known about high tested negative for BRCA1/2 mutations. Methods A retrospective, multicenter cohort study was performed 1996 to 2011 and comprised 6,235 women with unilateral 6,230 had ( n = 1,154) 575) mutations 4,501). Cumulative risks were calculated using Kaplan-Meier product-limit method compared between groups log-rank test....
Health benefits of the Mediterranean Diet (MD) have been shown in different at-risk populations. A German translation Adherence Screener (MEDAS) from PREvención con DIeta MEDiterránea (PREDIMED) consortium was used LIBRE study, investigating effects lifestyle-intervention on women with BRCA1/2 mutations. The purpose present study is to validate MEDAS version. a multicentre (three university hospitals during this pilot phase), unblinded, randomized, controlled clinical trial. Women mutation...
There is no international consensus up to which age women with a diagnosis of triple-negative breast cancer (TNBC) and family history or ovarian should be offered genetic testing for germline BRCA1 BRCA2 (gBRCA) mutations. Here, we explored the association at TNBC prevalence pathogenic gBRCA mutations in this patient group. The study comprised 802 (median 40 years, range 19–76) oestrogen receptor, progesterone human epidermal growth factor receptor type 2 negative cancers, who had relatives...
Guideline recommendations for the treatment of breast cancer with low hormone receptor (HR) expression (1%-9%) are ambiguous and several studies showed more similarities HR-negative tumors than HR strongly positive (≥10%). We used a population-based 15-year cohort to compare patient characteristics outcome tumors, respectively.A total 38 560 women diagnosed early invasive between 2004 2018 within scope Munich Cancer Registry 4.9 million inhabitants were included. Descriptive analyses...
Abstract Background Response to immune checkpoint blockade (ICB) in ovarian cancer remains disappointing. Several studies have identified the chemokine CXCL9 as a robust prognosticator of improved survival and characteristic immunoreactive subtype, which predicts ICB response. However, function has been poorly studied. Methods Impact Cxcl9 overexpression murine ID8- Trp53 −/− −/– Brca2 models on survival, cellular composition, PD-L1 expression anti-PD-L1 therapy. analysis subtypes...
A recent study presented first evidence that a single nucleotide polymorphism (SNP) at codon 388 of fibroblast growth factor receptor 4 (FGFR4) gene, causing transmembrane domain missense mutation (Gly388Arg), is associated with disease outcome in node-positive breast cancer. This article addresses the clinical relevance this SNP, FGFR4 genotype, phenotype, and HER2 regarding patient influence adjuvant systemic therapy substantial primary cancer collective (n = 372; median follow-up, 94.5...
Abstract To understand the biological basis of resistance to endocrine therapy is utmost importance in patients with steroid hormone receptor–positive breast cancer. Not only will this allow us prediction success, it may also lead novel therapies for resistant current therapy. DNA methylation promoter regions genes a prominent epigenetic gene silencing mechanism that contributes cancer biology. In study, we investigated whether could be associated recurrent Using microarray-based technology,...
The micronucleus assay (MNT) in human lymphocytes is frequently used to assess chromosomal damage as a consequence of environmental mutagen exposure, the effect mutagens or search for reduced DNA repair capacity after mutagenic challenge. We have established an automated scoring procedure cytokinesis blocked MNT based on computerized image analysis (Metasystems Metafer 4 version 2.12). To evaluate results we reproducibility counts, dose–response curve γ-irradiation and ability system...
Dihydropyrimidine dehydrogenase (DPD) is the initial enzyme acting in catabolism of widely used antineoplastic agent 5-fluorouracil (5FU). DPD deficiency known to cause a potentially lethal toxicity following administration 5FU. Here, we report novel genetic mechanisms underlying patients presenting with grade III/IV 5FU-associated toxicity. In one patient genomic DPYD deletion exons 21-23 was observed. five deep intronic mutation c.1129-5923C>G identified creating cryptic splice donor site....
Cancer patients carrying mutations in the dihydropyrimidine dehydrogenase gene (DPYD) have a high risk to experience severe drug-adverse effects following chemotherapy with fluoropyrimidine drugs such as 5-fluorouracil (5-FU) or capecitabine. The pretreatment detection of this impairment pyrimidine catabolism could prevent serious, potentially lethal side effects. As known deleterious explain only limited proportion events, we systematically searched for additional DPYD variations associated...